ClinicalTrials.gg
RecruitingNCT06748209TMSUpdated May 6, 2026

Establishing Mobile Transcranial Magnetic Stimulation

A Phase 4 interventional study of Left prefrontal Transcranial Magnetic Stimulation (TMS) and FDA cleared TMS for treating depression in Treatment Resistant Major Depression, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Medical University of South Carolina · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
22 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Depression by Medical University of South Carolina — 17 open to participants now, 21 under way, none of them phase 3. Depression · Medical University of South Carolina.

Planned enrollment
30th of 45
30 · median 46
Started
2025
with 5 others
Phase 4
3 of 47
1 open now
Primary completion
2027-03
later than 6 of 20 live
Registered
35th of 47
by date

Among the 47 studies in Depression by Medical University of South Carolina, this one is the 30th largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2025, is one of 3 in phase 4, reaches primary completion later than 6 of the 20 other live ones, and was the 35th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

17 of the 47 studies in Depression by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 22 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Depression by Medical University of South Carolina, or all of them as a file.
02

Study summary

In this pilot study, investigators propose to design and create a portable TMS unit, in a van, and then test out delivering TMS in three different locations in South Carolina, all affiliated with MUSC and within 2-hours driving from Charleston, SC. This study would test out this new delivery mode, and provide valuable feasibility, safety, and efficacy lessons for later refinement and potential widespread adoption of mobile TMS as a treatment option, both in our state and across the US.

Read the detailed description

In this pilot study, investigators propose to design and create a portable TMS unit, in a van, and then test out delivering TMS in three different locations in South Carolina, all within 90 minutes driving from Charleston, SC. This study would test out this new delivery mode, and provide valuable lessons for later refinement and potential widespread adoption of mobile TMS as a treatment option. This would open up access to TMS for millions of patients with treatment resistant depression who cannot be treated in the current model. After this pilot feasibility and efficacy study, future research would use mobile TMS units for siting at residential care facilities, or remote hospitals and clinics.

Investigators aim to determine whether it is possible to assemble and build a functioning mobile TMS unit. After assembling the van, investigators will then recruit up to 30 treatment-resistant depression patients who live near one of three satellite MUSC clinics. These clinics are all within a 2 hour drive from the MUSC Charleston campus. Investigators will treat these patients, open label, with FDA approved accelerated TMS (6 sessions each day, over 2 hours, for 5 days, spread over one or two weeks). Investigators will measure TMS effectiveness using standard depression rating scales. Importantly, investigators will also collect the costs of performing the TMS which will inform whether MUSC or other health delivery systems might adopt this TMS method.

03

Conditions studied

  • Treatment Resistant Major Depression

Browse trials for

Keywords

  • Anxiety
  • Depression
04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 30 is below the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.

Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
22 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (22-80 years old)
  • Have treatment-resistant depression as defined by the e-Mini, and the antidepressant treatment history form (ATHF short).
  • Be able to read and communicate in English.
  • Able to provide their own consent.
  • Access to a computer with videoconferencing ability for initial consent and telescreen.

Exclusion criteria

Exclusion Criteria:

  • Patients with unstable medical conditions that might make TMS unsafe. This includes current poorly controlled seizures.
  • Ferromagnetic metal in the head.
  • Pregnant.
  • Currently active substance abuse except tobacco.
06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Open label Clinical TMS for Depression

    This will be FDA approved Left Prefrontal TMS for treating depression, we will be performing this within a VA, located at clinics throughout SC.

    Device: Left prefrontal Transcranial Magnetic Stimulation (TMS) · Device: FDA cleared TMS for treating depression

Interventions

  • DeviceLeft prefrontal Transcranial Magnetic Stimulation (TMS)

    FDA cleared TMS

  • DeviceFDA cleared TMS for treating depression

    This is FDA approved TMS

07

What researchers measure

Primary outcomes

  1. Percent of depression responders

    Number of patients with \>50% improvement in Phq-9 scores before and then after 5 days of treatment

    Time frame: From baseline to 1 week immediately after treatment week

  2. Improvement in Depression Symptoms

    Change in Phq-9 ratings from baseline to end of treatment

    Time frame: From baseline to 1 week immediately after treatment week

08

Study locations

1 of 1 sites recruiting
  • Medical Univerity of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes — age, gender, degree of treatment resistance, current medications, changes in depression scores

Supporting information: Study protocol, Informed consent form

Time frame: After conclusion of the study and for 5 years after publication.

Access criteria: All credible investigators, by writing and asking permission from the study PI and team.

Data sharing details ↗ · scresearch.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2027, 21 months after the start.

Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 21 months is below that.

Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Dec 27, 2024
StartActual
May 10, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06748209
Responsible party
Mark George (Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Dec 27, 2024
Start date
May 10, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
May 6, 2026

Study contacts

Mark S George, MD
Contact
GEORGEM@MUSC.EDU
8438765142
Alexandra Herron, BA
Contact
herronal@musc.edu
Mark George, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion